Literature DB >> 28033655

Idarucizumab for urgent reversal of dabigatran for heart transplant: A case report.

Jessica Rimsans1, Megan Rhoten1, Katelyn Sylvester1, Steve K Singh2, Jean M Connors3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28033655     DOI: 10.1002/ajh.24638

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Idarucizumab (Praxbind®) for dabigatran reversal in patients undergoing heart transplantation: a cohort of ten patients.

Authors:  Eran Kalmanovich; Pascal Battistella; Philippe Rouviere; Bernard Albat; Jean-Marc Frapier; Roland Demaria; Fabien Huet; Audrey Agullo; Marc Mourad; Pascal Colson; Florence Leclercq; Philippe Gaudard; François Roubille
Journal:  Future Sci OA       Date:  2021-02-15

3.  Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report.

Authors:  António Tralhão; Carlos Aguiar; Jorge Ferreira; Maria José Rebocho; Emília Santos; Dinis Martins; José Pedro Neves
Journal:  Thromb J       Date:  2017-09-05

4.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04

5.  Use of Idarucizumab to Revert the Anticoagulant Effect of Dabigatran in Heart Transplant Surgery: An Institutional Experience.

Authors:  Álvaro Herrera-Escandón; Orlando Castaño-Cifuentes; Carlos A Plata-Mosquera
Journal:  Case Rep Cardiol       Date:  2020-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.